Skip navigation
More than 500,000* patients treated to date
WoundHome Infusion
George - Profiling a Vascular Surgery Patient With a MRSA Wound Infection

Presentation & History George is a 63-year-old, overweight white male who is recovering on the cardiac care wing of a teaching hospital following femoral popliteal bypass surgery in the right leg. Past medical history includes poorly controlled diabetes, hypertension, and a 2-pack-a-day smoking habit for the past 35 years.

It is significant that this hospital has noted an increased incidence of MRSA infections in postsurgical patients over the past 2 years.

Examination: temperature 100.8°F, pulse 98, RR 16, BP 145/90, a middle-aged male in no acute distress
  • Lungs: clear to auscultation, bilaterally
  • Extremities: popliteal pulse is good, on left side pulse is double; surgical site appears erythematous; no discharge is observed
  • Medications include antihypertensives and hypoglycemics

The patient has a white blood cell count of 12,000 with 85% neutrophils and 5% bands. His BUN/creatinine is 23/1.3.

A wound culture of the surgical site showed Gram-positive cocci.

The initial diagnosis is complicated skin infection at the surgical site with presumptive MRSA (later confirmed by culture).

This profile is for educational purposes only and is not based on an actual patient.
Actual diagnoses and treatments must be determined by attending physicians.

Proven clinical success of CUBICIN 4 mg/kg once daily in complicated skin infections, including MRSA and MSSA1*


CUBICIN once daily for complicated skin infections and bacteremia caused by S. aureus


CLCR = creatinine clearance; CAPD = continuous ambulatory peritoneal dialysis.

  • Once daily 30-minute, 50-mL infusion
  • No required monitoring of drug level in blood
  • Low potential for drug-drug interactions (not metabolized via CYP450)

Reference: 1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2004;38:1673-1681.


WoundHome Infusion
Angela - Profiling Home Infusion Therapy for a MRSA Skin Infection

Presentation & History Angela is a 47-year-old Hispanic female with a history of recurrent foot ulcers. She presents with an open wound on her left foot that developed 3 weeks ago. The patient reports pain in the area. Purulent discharge is present upon pressure to the affected area.

  • Prior hospitalization 6 months ago for a similar ulcerated infection of the foot
    • Vancomycin administered in-patient
    • Discharged on oral antibiotic therapy
    • Physician reports that patient may have been noncompliant with oral therapy
  • History of diabetes, depression, and hypertension
    • Medications include an oral hypoglycemic, a selective serotonin reuptake inhibitor (SSRI), and an antihypertensive
  • Examination: temperature 100.7°F, pulse 90, RR 16, BP 135/80, middle-aged female
    • Lungs: clear to auscultation, bilaterally
    • Heart: S3 gallop, regular rhythm
    • HEENT: pupils reactive, no lesions
    • Extremities: decreased sensation to light touch in both feet; 1+ pitting, pretibial edema, bilaterally; dorsalis pedis pulse palpable, but weak; 3.5-cm erosive lesion on the side of the first metatarsophalangeal joint, with purulent discharge, erythema, and tenderness

A wound culture of the site showed Gram-positive cocci.

The presumptive diagnosis is MRSA complicated skin infection.

  • Patient reports concern for maintaining her work and personal schedules
  • Physician and patient agree home infusion therapy is an appropriate choice for managing this infection

This profile is for educational purposes only and is not based on an actual patient.
Actual diagnoses and treatments must be determined by attending physicians.

Proven clinical success of CUBICIN 4 mg/kg once daily in complicated skin infections, including MRSA and MSSA1*


CUBICIN once daily for complicated skin infections and bacteremia caused by S. aureus


CLCR = creatinine clearance; CAPD = continuous ambulatory peritoneal dialysis.

  • Once daily 30-minute, 50-mL infusion
  • No required monitoring of drug level in blood
  • Can be given by peripheral line, midline, or peripherally inserted central catheter
  • Low potential for drug-drug interactions (not metabolized via CYP450)
    • No known drug-drug interactions with SSRIs
  • Permanent J-code reimbursement: J0878
    • 24-hour hotline: 1-866-RX-DAPTO

References: 1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for Clin Infect Dis. 2004;38:1673-1681. The treatment of complicated skin and skin structure infections. 2. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538-2544.

CUBICIN: MORE THAN 500,000* PATIENTS TREATED TO DATE
  • CUBICIN approved for complicated skin infections in 2003 and S. aureus bacteremia, including right-sided endocarditis, in 2006
  • In vitro activity against clinically important Gram-positive pathogens, including MSSA, MRSA, and vancomycin-resistant Enterococcus
  • Rapidly bactericidal in vitro† against certain Gram-positive pathogens

* Estimated number of patients treated based on sales through March 2008.
† The clinical relevance of in vitro data has not been established.